Puma Aims To File Nerlynx In Third-line HER2-positive Breast Cancer By July

Puma's CEO voiced confidence the biotech's lead asset Nerlynx will be approved in third-line HER2-positive metastatic breast cancer after its Phase III NALA study met co-primary endpoints.

Carcinoma
Filings to be based on Positive top line results from Phase III NALA trial • Source: Shutterstock

Positive top-line Phase III data testing Puma Biotechnology Inc.'s Nerlynx (neratinib) in third-line HER2-positive metastatic breast cancer, released this week will lead to talks with US and European regulators and follow-up filings for approval in that indication by next July, according to the biotech's CEO.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

More from Therapy Areas